Physiologically based biokinetic model of bioactivation and detoxification of the alkenylbenzene methyleugenol in rat.
The present study defines a physiologically based biokinetic (PBBK) model for the alkenylbenzene methyleugenol in rat based on in vitro metabolic parameters determined using relevant tissue fractions, in silico derived partition coefficients, and physiological parameters derived from the literature. The model was based on the model previously developed for the related alkenylbenzene estragole and consists of eight compartments including liver, lung, and kidney as metabolizing compartments, and separate compartments for fat, arterial blood, venous blood, richly perfused and slowly perfused tissues. Evaluation of the model was performed by comparing the PBBK predicted concentration of methyleugenol in the venous compartment to methyleugenol plasma levels reported in the literature, by comparing the PBBK predicted dose-dependent percentage of formation of 2-hydroxy-4,5-dimethoxyallylbenzene, 3-hydroxy-4-methoxyallylbenzene, and 1'-hydroxymethyleugenol glucuronide to the corresponding percentage of metabolites excreted in urine reported in the literature, which were demonstrated to be in the same order of magnitude. With the model obtained the relative extent of bioactivation and detoxification of methyleugenol at different oral doses was examined. At low doses, formation of 3-(3,4-dimethoxyphenyl)-2-propen-1-ol and methyleugenol-2',3'-oxide leading to detoxification appear to be the major metabolic pathways, occurring in the liver. At high doses, the model reveals a relative increase in the formation of the proximate carcinogenic metabolite 1'-hydroxymethyleugenol, occurring in the liver. This relative increase in formation of 1'-hydroxymethyleugenol leads to a relative increase in formation of 1'-hydroxymethyleugenol glucuronide, 1'-oxomethyleugenol, and 1'-sulfooxymethyleugenol the latter being the ultimate carcinogenic metabolite of methyleugenol. These results indicate that the relative importance of different metabolic pathways of methyleugenol may vary in a dose-dependent way, leading to a relative increase in bioactiviation of methyleugenol at higher doses.
Al-Subeihi
Ala A A
AA
Division of Toxicology, Wageningen University, Wageningen, The Netherlands. ala.alsubeihi@wur.nl
Spenkelink
Bert
B
Rachmawati
Novalia
N
Boersma
Marelle G
MG
Punt
Ans
A
Vervoort
Jacques
J
van Bladeren
Peter J
PJ
Rietjens
Ivonne M C M
IM
D000475:Alkenes / Q000737:chemistry*; D000818:Animals; D055162:Biocatalysis; D001711:Biotransformation; D002273:Carcinogens / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics*; D019295:Computational Biology; D004305:Dose-Response Relationship, Drug; D005054:Eugenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics; D005103:Expert Systems; D005260:Female; D007700:Kinetics; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism*; D008954:Models, Biological; D009153:Mutagens / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics*; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D012727:Sex Characteristics; D013045:Species Specificity
D000475:Alkenes; D002273:Carcinogens; D009153:Mutagens; D005054:Eugenol; C108731:1'-(hydroxymethyl)eugenol